PDCD1 and cholangiocarcinoma: Based on phase II study of pembrolizumab, a PD-1 inhibitor with a combination of the chemotherapeutic scheme of mFOLFOX6 (leucovorin, 5-fluorouracil, oxaliplatin) for advanced CCA [68], however, the application of pembrolizumab for CCA is still under study.